File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Issues in second trimester induced abortion (medical/surgical methods)

TitleIssues in second trimester induced abortion (medical/surgical methods)
Authors
Keywordsdilation and evacuation
mifepristone
misoprostol
second trimester abortion
Issue Date2010
PublisherBailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/bpobgyn
Citation
Best Practice And Research: Clinical Obstetrics And Gynaecology, 2010, v. 24 n. 4, p. 517-527 How to Cite?
AbstractSecond trimester abortion remains a common procedure worldwide. Dilatation and evacuation (D&E) is the surgical method of choice, if the surgical expertise and facilities are available. Adequate cervical dilatation preoperatively is a prerequisite for a safe D&E. Medical abortion using misoprostol together with mifepristone is the medical method of choice. The recommended regimen is 200 mg mifepristone followed by 800 μg of vaginal misoprostol 36-48 h later. Subsequent doses of 400 μg of misoprostol can be given orally every 3 h up to a maximum of four more doses. Proper preoperative assessment would not only help to provide safe abortion treatment, but it also guides the choice of method. If the expertise and facilities of both methods are available, both methods should be discussed and offered to the patient so that the patient can make an informed choice. © 2010 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/129421
ISSN
2021 Impact Factor: 4.268
2020 SCImago Journal Rankings: 1.622
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, VCYen_HK
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-12-23T08:37:03Z-
dc.date.available2010-12-23T08:37:03Z-
dc.date.issued2010en_HK
dc.identifier.citationBest Practice And Research: Clinical Obstetrics And Gynaecology, 2010, v. 24 n. 4, p. 517-527en_HK
dc.identifier.issn1521-6934en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129421-
dc.description.abstractSecond trimester abortion remains a common procedure worldwide. Dilatation and evacuation (D&E) is the surgical method of choice, if the surgical expertise and facilities are available. Adequate cervical dilatation preoperatively is a prerequisite for a safe D&E. Medical abortion using misoprostol together with mifepristone is the medical method of choice. The recommended regimen is 200 mg mifepristone followed by 800 μg of vaginal misoprostol 36-48 h later. Subsequent doses of 400 μg of misoprostol can be given orally every 3 h up to a maximum of four more doses. Proper preoperative assessment would not only help to provide safe abortion treatment, but it also guides the choice of method. If the expertise and facilities of both methods are available, both methods should be discussed and offered to the patient so that the patient can make an informed choice. © 2010 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_US
dc.publisherBailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/bpobgynen_HK
dc.relation.ispartofBest Practice and Research: Clinical Obstetrics and Gynaecologyen_HK
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectdilation and evacuationen_HK
dc.subjectmifepristoneen_HK
dc.subjectmisoprostolen_HK
dc.subjectsecond trimester abortionen_HK
dc.subject.meshAbortifacient Agents - administration and dosage-
dc.subject.meshAbortion, Induced - methods-
dc.subject.meshPatient Selection-
dc.subject.meshPregnancy Trimester, Second-
dc.subject.meshVacuum Curettage-
dc.titleIssues in second trimester induced abortion (medical/surgical methods)en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1521-6934&volume=24&issue=4&spage=517&epage=527&date=2010&atitle=Issues+in+second+trimester+induced+abortion+(medical/surgical+methods)-
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1016/j.bpobgyn.2010.02.008en_HK
dc.identifier.pmid20347397-
dc.identifier.scopuseid_2-s2.0-77956648253en_HK
dc.identifier.hkuros176860en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956648253&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue4en_HK
dc.identifier.spage517en_HK
dc.identifier.epage527en_HK
dc.identifier.isiWOS:000280984000009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLee, VCY=35758969300en_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK
dc.identifier.issnl1521-6934-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats